Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000636 · ClinicalTrials.gov registry record · NA
Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 2,000
- Enrollment target
NCT00000636 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,000 participants.
The verdict
NCT00000636, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
To evaluate and compare the effectiveness of a 2-month regimen of rifampin and pyrazinamide versus a 1-year course of isoniazid (INH) to prevent the development of tuberculosis in patients who are coinfected with HIV and latent Mycobacterium tuberculosis (MTb). Current guidelines recommend 6 to 12 months of treatment with INH for purified protein derivative (PPD)-positive individuals. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to INH-resistant organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more effective than longer courses of INH. A two-month prevention course should help to increase compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome problems with drug resistance.
Interventions
- DRUG Rifampin
- DRUG Pyrazinamide
- DRUG Isoniazid
- DRUG Pyridoxine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Est. Completion | 1997-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000636
The ClinicalTrials.gov registry entry for NCT00000636 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rifampin is the first listed.
NCT00000636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000636 about?
NCT00000636 is a clinical study titled "Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection". To evaluate and compare the effectiveness of a 2-month regimen of rifampin and pyrazinamide versus a 1-year course of isoniazid (INH) to prevent the development of tuberculosis in patients who are coinfected with HIV and latent Mycobacterium tuberculosis (MTb). Current guidelines recommend 6 to 12 ...
What is the current status of trial NCT00000636?
This trial is currently completed. It is a NA study. The enrollment target is 2,000 participants. Estimated completion is 1997-10.
What interventions are being tested in trial NCT00000636?
The interventions under investigation include: Rifampin (DRUG), Pyrazinamide (DRUG), Isoniazid (DRUG), Pyridoxine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00000636?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.